Navigation Links
The American Society for Microbiology honors Anthony R. Richardson
Date:6/7/2012

Washington, DCJune 6, 2012 Anthony R. Richardson, Ph.D., Assistant Professor, Department of Microbiology & Immunology, University of North Carolina Hill School of Medicine, has been honored with one of two 2012 Merck Irving S. Sigal Memorial Awards. These awards, given annually to two young scientists to recognize and award excellence in basic research in medical microbiology and infectious diseases, are presented in memory of Irving S. Sigal, an instrumental figure in the early discovery of therapies to treat HIV/AIDS. "Richardson is a remarkably imaginative scientist whose work bridges microbial physiology, metabolism, and pathogenesis," states his nominator, William Goldman from the University of North Carolina. "His approach is interdisciplinary and mechanistic, and his work has profound implications for understanding the evolution and emergence of highly virulent pathogens."

Richardson received his B.S. in genetic and bioengineering from Purdue University, and his Ph.D. in microbiology and molecular genetics from Emory University. He completed his postdoctoral fellowship in bacterial physiology and pathogenesis at the University of Washington, where he worked in the laboratory of Ferric Fang, who described Richardson as "extremely curious, interactive, and remarkably well readan exceedingly bright and creative scientist who is poised to make major contributions to the field of bacterial pathogenesis."

Richardson's research has always been focused on the role of basic bacterial physiology in the virulence of important human pathogens. As a graduate student, he investigated the role of DNA repair in modulating immune avoidance in epidemic meningococcal meningitis. His findings showed that the rapid host-to-host spread of Neisseria meningitidis in sub-Saharan Africa during seasonal epidemics selected for strains lacking certain aspects of DNA repair. Given the nature of N. menigitidis, this resulted in bacterial populations with extremely diversified surface immunogenicity facilitating rapid adaptation to new hosts.

As a postdoctoral fellow, Dr. Richardson continued studying bacterial metabolism in the context of its interaction with host innate immunity. He showed that host-production of nitric oxide (NO), a broad-spectrum immune effector, targeted multiple metabolic enzymes inhibiting the growth of pathogenic bacteria. In contrast, he found that the human pathogen Staphylococcus aureus, unlike all other tested bacteria including coagulase negative staphylococci, was able to resist the cytotoxic effects of host NO and thrive in its presence. S. aureus NO-resistance was shown to be essential for full virulence and hinged on the ability of the bacterium to evoke a metabolic state inherently resistant to the effects of this immune radical.

In 2008, Dr. Richardson established his laboratory at the University of North Carolina at Chapel Hill, focusing on the metabolic adaptations of S. aureus to host immunitywork that was soon featured as a Science cover article. Richardson's research studies how the availability of host arginine affects the outcomes of S. aureus infections. While the host converts free arginine to NO in response to inflammatory stimuli, arginine can also be converted to a class of compounds known as polyamines under similar conditions. S. aureus can resist the effects of NO, but for unknown reasons certain species of polyamines are lethal to the pathogen. Dr. Richardson's laboratory studies the battle between the host and S. aureus over the fate of free arginine. Mark Smeltzer, University of Arkansas for Medical Sciences, calls his work "both insightful and scientifically compelling, without exception."

Richardson's late graduate mentor, Igor Stojilijkovic, summarized Richardson to Fang: "He has a big brain, but his heart is even bigger. He is one of those rare individuals who you know will make it in any endeavor he chooses to follow."


'/>"/>

Contact: Garth Hogan
ghogan@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. News from the October 2008 Journal of the American Dietetic Association
2. American Chemical Societys Weekly PressPac -- Sept. 24, 2008
3. Nanotech and synbio: Americans dont know whats coming
4. American Chemical Societys Weekly PressPac
5. American College of Medical Genetics receives $13.5M NIH contract
6. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
7. American Chemical Society Weekly PressPac Oct. 15, 2008
8. Scientists map soils on an extinct American volcano
9. Indiana University research at American Public Health Association meeting
10. North American environmental commission launches trinational vaquita conservation plan
11. News from the November 2008 Journal of the American Dietetic Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology: